Almirall (Spain)

Recent papers from Almirall (Spain)

1. Lebrikizumab Provides Stable and Deep Long-Term Response with No/Minimal Fluctuations up to 3 Years in Patients with Moderate-to-Severe Atopic DermatitisDermatology and Therapy · 2026
2. Long-term efficacy of lebrikizumab in treating head, neck and face involvement in patients with moderate-to-severe atopic dermatitisJournal of Dermatological Treatment · 2026
3. singIST: an R/bioconductor library and quarto dashboard for automated single-cell comparative transcriptomics analysis of disease models and humansFrontiers in Genetics · 2026
4. Intestinal barrier dysfunction assessed by confocal laser endomicroscopy correlates with cirrhosis severity and clinical outcome☆JHEP Reports · 2026
5. Adherence to CAL/BDP PAD-Cream Influences Treatment Effectiveness and Preference in Scalp Psoriasis Under Real-Life Conditions: Results from the Prospective, Multicenter, Observational PRO-SCALP StudyDermatology and Therapy · 2026
6. Real-world use, perception, satisfaction and adherence of calcipotriol and betamethasone dipropionate PAD-cream in patients with plaque psoriasis in Spain: cross-sectional online surveyRevista Medicina Cutánea Ibero-Latino-Americana · 2026
7. Discovery ofLAS194046: A Potent and Selective pan-JanusKinase (JAK) Inhibitor with a Suitable Profile for Inhaled AdministrationJournal of Medicinal Chemistry · 2026
8. Reorganization and functional divergence of the CD4+ memory T cell compartment in hidradenitis suppurativaFrontiers in Immunology · 2026
9. Early Response to Calcipotriol and Betamethasone Dipropionate PAD-Cream at Week 4 in Patients with Mild-to-Moderate Plaque Psoriasis: A Post-Hoc Pooled Analysis of Two Phase III TrialsDermatology and Therapy · 2026
10. Imaging-guided tape stripping reveals consistent stratum corneum profiling of disease severity and treatment-responsive molecular features in pediatric atopic dermatitisJournal of Dermatological Science · 2026
11. Letter to the Editor Regarding “Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis”Dermatology and Therapy · 2026
12. Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)Dermatology and Therapy · 2026
13. A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment AdherenceDermatology and Therapy · 2026
14. Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 TrialsActa Dermato Venereologica · 2026
15. Patient-Reported Well-Being in Value-Based Routine Care in Psoriatic Disease Using Tildrakizumab: 2-Year Data of the Phase IV POSITIVE StudyPsoriasis Targets and Therapy · 2026
16. Overcoming measurement challenges in clinical practice: a deep learning-based approach to monocular surface area measurementSkin Health and Disease · 2026
17. Patient and clinician reported outcomes of calcipotriol/betamethasone dipropionate PAD-cream for the treatment of adult patients with scalp psoriasis under real-world conditions: results from the prospective, non-interventional, multicentre PRO-SCALP study.2026
18. Organoleptic Evaluation, User Acceptability, and Cosmetic Safety of Physiorelax Forte Plus Formulations in a Pediatric PopulationCosmetics · 2026
19. Understanding Clinical Inertia in Atopic Dermatitis: A Mixed-Methods Study of Barriers to Treatment EscalationDermatology and Therapy · 2026
20. Patient- and clinician-reported outcomes, safety and efficacy profile of tirbanibulin 1% for actinic keratosis under conditions close to routine clinical practice in Spain and Italy (TIRBASKIN study)Actas Dermo-Sifiliográficas · 2026